Compare Natco Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PFIZER NATCO PHARMA/
PFIZER
 
P/E (TTM) x 15.6 33.5 46.7% View Chart
P/BV x 3.1 5.6 54.7% View Chart
Dividend Yield % 1.5 0.6 239.0%  

Financials

 NATCO PHARMA   PFIZER
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
PFIZER
Mar-18
NATCO PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,0802,365 45.7%   
Low Rs6711,625 41.3%   
Sales per share (Unadj.) Rs592.1430.3 137.6%  
Earnings per share (Unadj.) Rs188.478.7 239.4%  
Cash flow per share (Unadj.) Rs206.393.2 221.4%  
Dividends per share (Unadj.) Rs8.2520.00 41.3%  
Dividend yield (eoy) %0.91.0 94.0%  
Book value per share (Unadj.) Rs833.6586.5 142.1%  
Shares outstanding (eoy) m36.9045.75 80.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.54.6 31.9%   
Avg P/E ratio x4.625.3 18.3%  
P/CF ratio (eoy) x4.221.4 19.8%  
Price / Book Value ratio x1.13.4 30.9%  
Dividend payout %4.425.4 17.2%   
Avg Mkt Cap Rs m32,31191,271 35.4%   
No. of employees `0004.82.6 183.7%   
Total wages/salary Rs m3,2563,143 103.6%   
Avg. sales/employee Rs Th4,522.57,484.8 60.4%   
Avg. wages/employee Rs Th674.01,195.0 56.4%   
Avg. net profit/employee Rs Th1,439.01,369.1 105.1%   
INCOME DATA
Net Sales Rs m21,84819,685 111.0%  
Other income Rs m4041,143 35.3%   
Total revenues Rs m22,25220,828 106.8%   
Gross profit Rs m9,2845,003 185.6%  
Depreciation Rs m662663 99.9%   
Interest Rs m1544 3,666.7%   
Profit before tax Rs m8,8725,479 161.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9201,878 102.2%   
Profit after tax Rs m6,9523,601 193.1%  
Gross profit margin %42.525.4 167.2%  
Effective tax rate %21.634.3 63.1%   
Net profit margin %31.818.3 174.0%  
BALANCE SHEET DATA
Current assets Rs m21,30724,167 88.2%   
Current liabilities Rs m5,9209,544 62.0%   
Net working cap to sales %70.474.3 94.8%  
Current ratio x3.62.5 142.1%  
Inventory Days Days7355 133.0%  
Debtors Days Days10729 371.1%  
Net fixed assets Rs m14,9869,514 157.5%   
Share capital Rs m369458 80.7%   
"Free" reserves Rs m30,35326,375 115.1%   
Net worth Rs m30,76026,832 114.6%   
Long term debt Rs m025 0.0%   
Total assets Rs m37,15136,900 100.7%  
Interest coverage x58.61,305.5 4.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 110.2%   
Return on assets %19.19.8 195.8%  
Return on equity %22.613.4 168.4%  
Return on capital %29.320.4 143.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32222 46,079.2%   
Fx outflow Rs m2,9781,489 200.1%   
Net fx Rs m7,343-1,466 -500.8%   
CASH FLOW
From Operations Rs m4,6363,318 139.7%  
From Investments Rs m-11,155-2,383 468.1%  
From Financial Activity Rs m6,509-1,104 -589.9%  
Net Cashflow Rs m-18-169 10.7%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 63.9 2.3%  
Indian inst/Mut Fund % 7.8 7.5 104.5%  
FIIs % 16.6 4.9 339.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 23.7 109.7%  
Shareholders   25,395 85,207 29.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ASTRAZENECA PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS